drugset / Trial / NCT00828763

GSK1349572 Mass Balance Study

NCT00828763

Phase 1 Completed 6 enrolled GlaxoSmithKline Shionogi · collab
NaSingle-groupOpen-labelTreatment

Summary

Mass balance study to determine the recovery of a single radiolabelled dose of GSK1349572 from urine and feces

Timeline

Start
2009-02
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dolutegravir Other / unclassified 20 mg Oral

Indications

No indication recorded.